Salil Kallianpur
The code of conduct for ethical pharmaceutical marketing was not designed for a world of data, software, and artificial intelligence. Already under severe pressure from COVID-19 and the changes that will lie in its wake, it is utterly inadequate to face the four main challenges that new technologies pose.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
